Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2010 Dec 1;20(23):7164-8. doi: 10.1016/j.bmcl.2010.07.059. Epub 2010 Jul 23.

The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: the three microdose candidates.

Author information

1
Pfizer Global Research and Development, Chesterfield, MO 63017, USA. jl47wang@yahoo.com

Abstract

In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t(1/2)=360 h) of the first clinical candidate 1 and human t(1/2) had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h.

PMID:
20728356
DOI:
10.1016/j.bmcl.2010.07.059
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center